Cytori Therapeutics (CYTX) Sees Large Volume Increase

Cytori Therapeutics Inc (NASDAQ:CYTX) shares saw unusually-high trading volume on Monday . Approximately 2,220,644 shares traded hands during mid-day trading, an increase of 491% from the previous session’s volume of 375,647 shares.The stock last traded at $0.43 and had previously closed at $0.38.

CYTX has been the subject of a number of research reports. ValuEngine raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 4th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Cytori Therapeutics in a report on Tuesday, September 18th. Zacks Investment Research raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Tuesday, July 31st. Finally, Maxim Group lowered shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Cytori Therapeutics has a consensus rating of “Buy” and a consensus price target of $10.56.

The firm has a market cap of $3.13 million, a price-to-earnings ratio of -0.06 and a beta of 2.52.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The company had revenue of $1.56 million during the quarter, compared to analyst estimates of $2.50 million. Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. On average, analysts anticipate that Cytori Therapeutics Inc will post -0.85 EPS for the current year.

About Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

Featured Story: How much money do you need to begin day trading?

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply